Skip to main content
Terug
Watch Compare

Sensei Biotherapeutics, Inc.

Datakwaliteit: 83%
SNSE
NASDAQ Manufacturing Chemicals
€ 28,70
▼ € 1,43 (-4,75%)
6 months return
—
Momentum
Neutral
ROE
-83,80%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-83,80%
Onder sectorgemiddelde (-54,68%)
ROIC-68,96%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio5,81
Interest Coverage-696,50

Waardering

PE (TTM)
-1,95
Onder sectorgemiddelde (-1,50)
P/B Ratio1,79
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -20,47 M

Price History

Financiële Trends

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q2 2026 · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q2 '26
Reported -€ 5,40 -€ 3,91 -€ 3,62 -€ 3,74 —
Estimate -€ 5,20 -€ 5,00 -€ 4,11 -€ 4,81 —
Verrassing -3,85% +21,80% +11,92% +22,25% —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -83,80% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -21,09 M
ROE -83,80% ROA -71,03%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -20,47 M
ROIC -68,96% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 5,81
Debt / Equity N/A Current Ratio 5,81
Interest Coverage -696,50 Asset Turnover N/A
Working Capital 21,35 M Tangible Book Value 23,01 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -1,95 · EV/EBITDA: N/A
P/E Ratio -1,95 Forward P/E N/A
P/B Ratio 1,79 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -49,75%
Market Cap 41,15 M Enterprise Value 30,58 M

Per Share

EPS: -16,72 · FCF/Share: -15,27
EPS (Diluted TTM) -16,72 Revenue / Share N/A
FCF / Share -15,27 OCF / Share -15,26
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 97,08% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 97,08%
SBC-Adj. FCF -22,18 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -21,09 M -30,16 M -34,10 M -48,59 M -36,79 M
EPS (Diluted) -16,72 -1,20 -1,22 -1,58 —
Gross Profit — — — — —
Operating Income -22,29 M -32,61 M -37,06 M -50,19 M -37,48 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses — — — — —
D&A 122.000,0 551.000,0 571.000,0 614.000,0 685.000,0
Interest Expense 32.000,0 90.000,0 144.000,0 219.000,0 670.000,0
Income Tax 0,0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 22,90 M 45,36 M 74,37 M 118,38 M 153,23 M
Total Liabilities 4,31 M 6,98 M 9,48 M 14,97 M 6,71 M
Shareholders' Equity 18,59 M 38,39 M 64,90 M 103,41 M 146,51 M
Total Debt — — — — 567.000,0
Cash & Equivalents 8,67 M 9,99 M 13,01 M 17,80 M 7,16 M
Current Assets 21,51 M 41,93 M 67,25 M 108,59 M 148,54 M
Current Liabilities 4,25 M 5,45 M 5,64 M 9,07 M 4,89 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -2,0 -1,5
P/B 1,8 1,6
ROE % -83,8 -54,7
Net Margin % — -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3